Histopathologic Changes in a Hypogonadal Male on Exogenous Testosterone Diagnosed with Prostatic Adenocarcinoma: A Case Report

In the United States, prostatic adenocarcinoma is the most common nonskin cancer and second leading cause of cancer death. Pathologic diagnostics are paramount to guiding treatment but require an awareness that hormonal treatments have the capacity to alter the histological appearance of prostate cancer. This case highlights the importance of accurate diagnostics and grading through a discussion of histological findings in an unusual case of a male patient with hypogonadism on long-Term exogenous testosterone who was diagnosed with prostatic adenocarcinoma.